Prospects for the use of the fibrinolytic drug streptokinase
DOI:
https://doi.org/10.18372/2306-6407.1.18033Keywords:
streptokinase, enzymes, fibrin, fibrinolytic drug, productionAbstract
The report considers the prospects of using the fibrinolytic drug streptokinase in the treatment of cardiovascular diseases. Special attention is paid to streptokinase as an effective means for the treatment of myocardial infarction, especially in economically weak countries. The advantages of using streptokinase in terms of efficiency and economic feasibility compared to other clot dissolvers are highlighted. The need for further research and optimization of the production technology of fibrinolytic enzymes to overcome the limitations associated with their use is explained.
References
Підлякова Н. А., Мацелюх О. В., Варбанець Л. Д. Фібринолітичні пептидази Bacillus // Мікробіологічний журнал. – 2013. – Т. 75(3). – С. 80–93.
Sharma C., Osmolovskiy A., Singh R. Microbial fibrinolytic enzymes as anti-thrombotics: production, characterisation and prodigious biopharmaceutical applications // Pharmaceutics. – 2021. – Vol. 13(11). – 1880. https://doi.org/10.3390/pharmaceutics13111880
Baggio L. M., Panagio L. A., Gasparin F. G. M., Sartori D., Celligoi M. A. P. C., Baldo C. Production of fibrinogenolytic and fibrinolytic enzymes by a strain of Penicillium sp. isolated from contaminated soil with industrial effluent // Acta Scientiarum. Health Sciences. – 2019. – Vol. 41(1). – e40606. https://doi.org/10.4025/actascihealthsci.v41i1.40606
Kunamneni A., Abdelghani T. T. A., Ellaiah P. Streptokinase – the drug of choice for thrombolytic therapy // Journal of Thrombosis and Thrombolysis. – 2006. – Vol. 23(1). – P. 9–23. https://doi.org/10.1007/s11239-006-9011-x
Hasanpour A., Esmaeili F., Hosseini H., Amani A. Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies // Mater Sci Eng C Mater Biol Appl. – 2021. – Vol. 118. – 111427. https://doi.org/10.1016/j.msec.2020.111427
